A home menopause test can detect a hormone signal without establishing whether someone is in menopause or perimenopause. Urine self-tests described by UK and US guidance look for raised follicle-stimulating hormone, usually shortened to FSH. A positive result is not a diagnosis, and a negative result does not rule out the menopause transition.
That distinction matters when a kit’s packaging turns a complex change into a yes-or-no question. There are two different claims to examine: whether a test detects its target, and whether that target answers the question the person actually has.
What an FSH strip measures
FSH is a hormone involved in ovarian function. A qualitative urine test reports whether the concentration crosses the test’s threshold; it does not provide a complete account of hormone patterns or symptoms.
The US Food and Drug Administration’s explanation of home FSH tests makes that boundary explicit. FSH can rise and fall during the menstrual cycle and the menopause transition. Detecting an elevated level on one occasion cannot establish the whole clinical picture.
An analytically successful test can therefore produce an unhelpful answer to a different question. Finding a hormone is not the same as identifying the cause of irregular periods, establishing a menopause stage or showing that pregnancy is no longer possible.
Why the UK guidance looks beyond the result
The NHS overview says there is no routine test for perimenopause and menopause; assessment may be based on age and symptoms. It defines menopause as twelve months without a period when hormonal contraception is not being used.
In its 2022 position on over-the-counter tests, the Royal College of Obstetricians and Gynaecologists advises against using urine FSH self-tests to detect menopause or perimenopause. Its concern is the narrowness of the measurement and fluctuating hormone levels. It also identifies hormonal contraception as a complication for interpreting these tests.
This is not a claim that all hormone testing has no clinical role. The NHS early-menopause guidance says a GP may sometimes use blood tests when someone under 45 has menopause symptoms. A clinician investigating a particular situation is asking a more specific question than a shop-bought strip can settle on its own.
Urine strips and mail-in blood tests are different services
“Menopause test” can refer to several products. A urine strip, a finger-prick blood sample sent to a laboratory and clinician-arranged investigations should not be treated as interchangeable.
For any report, the useful distinctions are the specimen, the hormone or hormones measured, whether the result is qualitative or numerical, and the interpretation being offered. A more detailed report may contain more measurements; that alone does not establish that it can diagnose the menopause transition.
The RCOG position cited here concerns urine FSH self-tests. This article does not compare the performance of mail-in panels or establish that all kits use the same method.
A negative test can still leave the original question open
A person may have symptoms and a negative strip because the measured hormone was not elevated at that particular time. Conversely, an elevated result does not explain every symptom or identify the most appropriate treatment.
The FDA also warns that these tests do not reliably determine fertility and should not be used as a reason to stop contraception. That is a limitation of the result’s meaning, rather than a question of how confidently a line can be read.
The most useful information to bring to a clinical conversation may therefore be the history that a strip leaves out: symptoms, changes in periods, medicines and the timing of any test. The NHS directs people who think they have menopause symptoms to a GP. A home result does not replace that assessment or need to settle the question before the conversation can begin.